PE20191556A1 - Compuestos de dinucleotidos ciclicos modificados - Google Patents
Compuestos de dinucleotidos ciclicos modificadosInfo
- Publication number
- PE20191556A1 PE20191556A1 PE2019001891A PE2019001891A PE20191556A1 PE 20191556 A1 PE20191556 A1 PE 20191556A1 PE 2019001891 A PE2019001891 A PE 2019001891A PE 2019001891 A PE2019001891 A PE 2019001891A PE 20191556 A1 PE20191556 A1 PE 20191556A1
- Authority
- PE
- Peru
- Prior art keywords
- modified cyclic
- compounds
- cyclic dinucleotide
- dinucleotide compounds
- pharmutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 abstract 2
- GFFGJBXGBJISGV-RVQWGROCSA-N 2,8-ditritio-7h-purin-6-amine Chemical compound [3H]C1=NC(N)=C2NC([3H])=NC2=N1 GFFGJBXGBJISGV-RVQWGROCSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- 229940075420 xanthine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Abstract
REFERIDO A COMPUESTOS DINUCLEOTIDOS CICLICOS MODIFICADOS DE FORMULA (I) DONDE LA BASE1 Y LA BASE2 SE SELECCIONAN DE PURINA, ADENINA, GUANINA, XANTINA E HIPOXANTINA, CONECTADAS MEDIANTE SUS ATOMOS DE N. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS AFINIDAD DE FIJACION AL ESTIMULADOR DE GENES DE INTERFERON (STING) HUMANO SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNITARIAS, ENFERMEDADES INFECCIOSAS, CANCER, Y COMO ADYUVANTES DE VACUNAS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17162392 | 2017-03-22 | ||
| PCT/EP2018/056656 WO2018172206A1 (en) | 2017-03-22 | 2018-03-16 | Modified cyclic dinucleotide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191556A1 true PE20191556A1 (es) | 2019-10-24 |
Family
ID=58412904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001891A PE20191556A1 (es) | 2017-03-22 | 2018-03-16 | Compuestos de dinucleotidos ciclicos modificados |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10392419B2 (es) |
| EP (1) | EP3601313B1 (es) |
| JP (2) | JP6742534B2 (es) |
| KR (1) | KR20190130612A (es) |
| CN (1) | CN110382515B (es) |
| AR (1) | AR111247A1 (es) |
| AU (1) | AU2018239468A1 (es) |
| BR (1) | BR112019017812A2 (es) |
| CA (1) | CA3056008A1 (es) |
| CL (1) | CL2019002590A1 (es) |
| CO (1) | CO2019010023A2 (es) |
| EA (1) | EA201992209A1 (es) |
| IL (1) | IL268799A (es) |
| JO (1) | JOP20190218A1 (es) |
| MX (1) | MX2019011281A (es) |
| PE (1) | PE20191556A1 (es) |
| PH (1) | PH12019502155A1 (es) |
| SG (1) | SG11201908567UA (es) |
| TW (1) | TW201842919A (es) |
| WO (1) | WO2018172206A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3017524A1 (en) | 2016-03-18 | 2017-09-21 | Immune Sensor, Llc | Cyclic di-nucleotide compounds and methods of use |
| JP7235512B2 (ja) * | 2016-06-24 | 2023-03-08 | バイオジェン・エムエイ・インコーポレイテッド | キャッピング工程を有さないチオール化オリゴヌクレオチドの合成 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JOP20190218A1 (ar) * | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CN111989338A (zh) * | 2018-03-27 | 2020-11-24 | 勃林格殷格翰国际有限公司 | 修饰的环二核苷酸化合物 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020117625A1 (en) * | 2018-12-07 | 2020-06-11 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| EP3891166A4 (en) * | 2018-12-07 | 2022-08-24 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| EP3891165A4 (en) * | 2018-12-07 | 2022-08-24 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| JP7604396B2 (ja) | 2019-05-10 | 2024-12-23 | 武田薬品工業株式会社 | 抗体薬物複合体 |
| EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| CN120324366A (zh) * | 2019-10-07 | 2025-07-18 | 总医院公司 | 肺表面活性物质-仿生纳米颗粒的组合物和方法 |
| JPWO2021206158A1 (es) | 2020-04-10 | 2021-10-14 | ||
| WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| US20220111028A1 (en) | 2020-10-14 | 2022-04-14 | Boehringer Ingelheim International Gmbh | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist |
| IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EP1740192B1 (en) | 2004-03-15 | 2012-06-13 | David K. R. Karaolis | Cyclic dinucleotide for stimulating the immune of inflammatory response |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| JP6023706B2 (ja) | 2010-07-09 | 2016-11-09 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． | Ｃｄ２７に対するアゴニスト抗体 |
| WO2014093936A1 (en) * | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| MX365661B (es) | 2012-12-19 | 2019-06-10 | Univ Texas | Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero. |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
| EP3027227A4 (en) | 2013-07-31 | 2018-05-23 | Memorial Sloan Kettering Cancer Center | Sting crystals and modulators |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| RS59853B1 (sr) | 2014-03-14 | 2020-02-28 | Novartis Ag | Molekuli anti-lag-3 antitela i njihove upotrebe |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| ES2764178T3 (es) | 2014-12-16 | 2020-06-02 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para inducción de citocinas |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR20170129802A (ko) * | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법 |
| WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2018009466A1 (en) * | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JOP20190218A1 (ar) * | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
-
2017
- 2017-06-16 JO JOP/2019/0218A patent/JOP20190218A1/ar unknown
-
2018
- 2018-03-16 JP JP2019552098A patent/JP6742534B2/ja active Active
- 2018-03-16 PE PE2019001891A patent/PE20191556A1/es unknown
- 2018-03-16 CA CA3056008A patent/CA3056008A1/en not_active Abandoned
- 2018-03-16 KR KR1020197030982A patent/KR20190130612A/ko not_active Withdrawn
- 2018-03-16 SG SG11201908567U patent/SG11201908567UA/en unknown
- 2018-03-16 MX MX2019011281A patent/MX2019011281A/es unknown
- 2018-03-16 CN CN201880016136.8A patent/CN110382515B/zh active Active
- 2018-03-16 WO PCT/EP2018/056656 patent/WO2018172206A1/en not_active Ceased
- 2018-03-16 BR BR112019017812-0A patent/BR112019017812A2/pt not_active Application Discontinuation
- 2018-03-16 EA EA201992209A patent/EA201992209A1/ru unknown
- 2018-03-16 EP EP18710069.8A patent/EP3601313B1/en active Active
- 2018-03-16 AU AU2018239468A patent/AU2018239468A1/en not_active Abandoned
- 2018-03-20 US US15/925,887 patent/US10392419B2/en active Active
- 2018-03-21 AR ARP180100663A patent/AR111247A1/es unknown
- 2018-03-21 TW TW107109571A patent/TW201842919A/zh unknown
-
2019
- 2019-08-20 IL IL26879919A patent/IL268799A/en unknown
- 2019-09-11 CL CL2019002590A patent/CL2019002590A1/es unknown
- 2019-09-16 CO CONC2019/0010023A patent/CO2019010023A2/es unknown
- 2019-09-20 PH PH12019502155A patent/PH12019502155A1/en unknown
-
2020
- 2020-07-28 JP JP2020127120A patent/JP2020203887A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201908567UA (en) | 2019-10-30 |
| CN110382515B (zh) | 2023-03-03 |
| KR20190130612A (ko) | 2019-11-22 |
| US20180273578A1 (en) | 2018-09-27 |
| CO2019010023A2 (es) | 2019-09-30 |
| US10392419B2 (en) | 2019-08-27 |
| CL2019002590A1 (es) | 2020-01-24 |
| PH12019502155A1 (en) | 2020-07-06 |
| WO2018172206A1 (en) | 2018-09-27 |
| EP3601313A1 (en) | 2020-02-05 |
| MX2019011281A (es) | 2019-11-01 |
| CA3056008A1 (en) | 2018-09-27 |
| JP6742534B2 (ja) | 2020-08-19 |
| CN110382515A (zh) | 2019-10-25 |
| TW201842919A (zh) | 2018-12-16 |
| AU2018239468A1 (en) | 2019-09-12 |
| BR112019017812A2 (pt) | 2020-03-31 |
| JOP20190218A1 (ar) | 2019-09-22 |
| EP3601313B1 (en) | 2021-03-10 |
| EA201992209A1 (ru) | 2020-03-16 |
| JP2020203887A (ja) | 2020-12-24 |
| JP2020514389A (ja) | 2020-05-21 |
| IL268799A (en) | 2019-10-31 |
| AR111247A1 (es) | 2019-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191556A1 (es) | Compuestos de dinucleotidos ciclicos modificados | |
| PE20191503A1 (es) | Compuestos de dinucleotidos ciclicos | |
| DOP2017000175A (es) | Dinucleótidos cíclicos útiles en el tratamiento del cáncer | |
| DOP2016000316A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
| CO2021000942A2 (es) | Compuestos 1h-pyrazolo [4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y métodos y usos de los mismos | |
| PE20181297A1 (es) | Dinucleotidos de purino ciclico como moduladores de sting | |
| UY35732A (es) | Composiciones terapéuticas de nucleótidos y nucleósidos y usos relacionados con las mismas | |
| MX2011007364A (es) | Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales. | |
| PE20160080A1 (es) | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon | |
| PE20180116A1 (es) | HETEROCICLILMETIL-TIENOURACILO COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2b | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| EA201791999A1 (ru) | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" | |
| ECSP12012282A (es) | Fosforamidatos de nucleósido | |
| UY33619A (es) | Analogos de nucleotidos sustituidos | |
| PH12018502606A1 (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| MY190867A (en) | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment | |
| PE20160120A1 (es) | Derivados de nucleosido 4'-fluoro-2'-metilo sustituido | |
| PE20170698A1 (es) | Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| BR112017027653A2 (pt) | método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos | |
| MX2021006992A (es) | Análogos de nucleósidos de ciclobutilo como antivirales. | |
| AR101679A2 (es) | Composiciones para el tratamiento antiviral combinado | |
| AR107325A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b, kit | |
| EA201592204A1 (ru) | Композиции и способы для активации передачи сигналов, зависящей от "стимулятора гена интерферона" |